|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that this polymorphism is a potential risk locus for psoriasis and that it results in a direct increase in IL-17F production.
|
31831764 |
2019 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
By conducting the MCCV on seed cross-talk, 3 hub cross-talk for BPD were uncovered: i) The pair of pathways role of interleukin-17F (IL-17F) in allergic inflammatory airway diseases and role of IL-17A in psoriasis; ii) the pair of pathways role of IL random forest 17A in psoriasis and IL-17A signaling in fibroblasts and ii) the pair of pathways IL-17A signaling in airway cells and role of hypercytokinemia/hyperchemokinemia in the pathogenesis of influenza.
|
30930971 |
2019 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although striking upregulation of TH17 pathway genes (IL17F and IL36B/G) resembling that seen in patients with psoriasis was common to all patients with ichthyoses in a severity-related manner, patients with Netherton syndrome showed the greatest T-cell activation (inducible costimulator [ICOS]) and a broader immune phenotype with T<sub>H</sub>1/IFN-γ, OASL, and T<sub>H</sub>2/IL-4 receptor/IL-5 skewing, although less than seen in patients with AD (all P < .05).
|
29803800 |
2019 |
|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One single nucleotide polymorphism (SNP) was analysed in IL-17A (rs10484879) and one SNP in IL-17F (rs763780) to look for an association with psoriasis.
|
30666004 |
2018 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Drug-mediated disruption of IL17A, IL17F and IL17RA proteins is effective in psoriasis.
|
30076642 |
2018 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
IκBζ (encoded by the NFKBIZ gene) plays a key role in the development of psoriasis by mediating IL-17A- and IL-17F-driven effects.
|
29938836 |
2018 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual neutralization of IL-17A and IL-17F with bimekizumab provided rapid and substantial clinical improvements in patients with psoriasis, with no unexpected or dose-related safety findings.
|
29609013 |
2018 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This article reviews the immunologic role of interleukin (IL)-17, the major effector cytokine in the pathogenesis of psoriatic disease, along with the rationale for targeting the IL-17 cytokine family (IL-17A, IL-17F, and IL-17 receptor A) in the treatment of psoriasis and psoriatic arthritis.
|
30109481 |
2018 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate analyses demonstrated that while changes in IL-17F are the most important predictor of improvement in Psoriasis Area and Severity Index scores, apremilast exerts synergistic attenuating effects among a key group of cytokines involved in the pathology of psoriasis, and these effects correlate with improved skin symptoms.
|
30124722 |
2018 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support the continued clinical development of bimekizumab for diseases mediated by both IL-17A and IL-17F, including psoriasis.
|
27859546 |
2017 |
|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we report two new psoriasis-susceptibility loci, in IL17F and JAK2, as well as a newly identified late-onset associated protective JAK2 locus and a protective JAK1 haplotype in the Korean population.
|
27774581 |
2017 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, we present IκBζ as a novel key regulator of IL-17F-driven effects in psoriasis.
|
27576147 |
2017 |
|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate an association between the IL17A (-197G>A; rs2275913) and IL17F (rs763780: T>C; rs11465553: G>A; rs2397084: T>C) polymorphisms with psoriasis susceptibility as well as response to topical and combined topical with narrow-band ultraviolet B (NB-UVB) therapy in a Polish population.
|
27591988 |
2016 |
|
Psoriasis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We analyzed three SNPs in IL-17A (rs2275913 and rs10484879) and IL-17F (rs763780) to look for an association with psoriasis and/or with response to anti-TNF drugs or ustekinumab.
|
26415694 |
2015 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using gene-targeted mice, we observed that loss of Il17a, Il17f, or Il22 strongly reduced disease the severity of psoriasis.
|
22546855 |
2012 |
|
Psoriasis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, IL-17F expression in skin biopsy specimens from psoriasis patients was examined by immunohistochemistry.
|
20148256 |
2010 |
|
Psoriasis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we demonstrate for the first time augmented protein levels of IL-17A, IL-17C and IL-17F in psoriatic skin lesions, indicating a possible role for IL-17C in addition to IL-17A and IL-17F in the pathogenesis of psoriasis.
|
19016708 |
2009 |
|
Psoriasis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Finally, IL-17F expression in skin biopsy samples from psoriasis patients were examined by western blotting and ELISA.
|
18830271 |
2009 |